President Trump has introduced a new government website, TrumpRx, designed to help patients purchase discounted prescription medications directly from pharmaceutical companies or through pharmacy coupon programs. Announced Thursday, the platform is aimed primarily at people willing to pay cash rather than use insurance. Administration officials say it could be especially helpful for those who are uninsured or underinsured. Trump said “millions of Americans” would save money and described the effort as “so good for overall health care.” However, CNBC reports that it remains unclear whether patients—particularly those with insurance coverage—will save more through the site than they do with their current purchasing methods.
The TrumpRx website does not process sales itself. Instead, it directs users to drugmakers’ direct-to-consumer programs or generates discount coupons that can be used at pharmacies. Several major pharmaceutical companies, including Eli Lilly and Novo Nordisk, have integrated their existing cash-discount programs into the platform, particularly for high-demand GLP-1 medications used to treat diabetes and obesity. According to the administration, example prices listed on TrumpRx include Ozempic starting at $199 per month, Wegovy at $199 for injections and $149 for starter pill doses, and Lilly’s Zepbound at $299—well below their list prices, which can exceed $1,000 per month. At least 16 drugmakers have reached agreements with the administration to offer select products at reduced prices, including arrangements tied to discounting certain medications for Medicaid as part of Trump’s “most favored nation” pricing initiative.
Some health policy experts have raised questions about how much insured patients would benefit. Juliette Cubanski of KFF noted that individuals with coverage and reasonable copays may see little financial advantage, and that purchases made outside insurance may not count toward deductibles or out-of-pocket maximums. Research cited by Georgetown University’s Medicare Policy Initiative and the Congressional Budget Office suggests that existing insurer and government discounts on brand-name drugs can already reduce list prices by 40% to more than 75%, potentially equaling or surpassing TrumpRx cash prices for many medications. The New York Times also reported that some of the most expensive drugs, including certain cancer treatments, are not currently listed on the TrumpRx site.
At the unveiling, Trump emphasized that the lower prices were achieved by pressuring pharmaceutical companies to match prices charged in other countries. He said prescription drug costs in foreign nations could rise as a result, according to the Associated Press. “You’re going to save a fortune,” Trump said.